1,275
-2.89%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Orient Bio
Its shares trade on KRX under the ticker 002630.KS. It has been listed since 28 December 1976. In the fiscal year to 31 March 2026, it reported revenue of ₩29.75bn and a net loss of ₩4.57bn. At that date it held total assets of ₩81.62bn and shareholders' equity of ₩68.54bn.
ORIENTBIO, Inc. engages in the research and development of biotechnology. The company is headquartered in Seongnam, Gyeonggi-Do. The firm produces and supplies laboratory animals, including mice, rats, guinea pigs, hamsters, specific pathogen free (SPF) rabbits, beagles and others. The company also provides contract research organization (CRO) services, including CRO safety assessment and CRO new drug development services; medical and library equipment, such as barrier systems, and support services such as rodent surgery services, laboratory diagnostics services, transgenic services, genetic testing services and other services. In addition, along with its subsidiaries, the Company provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 28 Dec 1976
- Employees
- 120
- Website
- orientbio.co.kr ↗
Leadership
Pay as last reported
- Jae Jin JangChairman of the Board, Chief Executive Officer
- Ms. Suk Jong ChoiVice Chairman of the Board, since 2006
- Yeong Cheol ShinVice President, since 2008
- Ju Min KimVice President, since 2008
- Sang Nyeon KimVice President
- Jae Gu ChoiInternal Auditor
- Mr. Gang Mun ChoiDirector
- Hae Eun JangDirector
- Mr. Yong Seok ChoNon-Executive Independent Director
- No Hyeon SungNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Orient Bio Inc. provides specialized laboratory animals including SPF rabbits and beagles for research.
- The company offers comprehensive CRO services for new drug development and safety assessments.
- Orient Bio Inc. supplies essential medical equipment like barrier systems for laboratories.
Weaknesses
- Orient Bio Inc. has limited employee count with only 120 full-time staff.
- The company's business spans multiple sectors including automobile components and power supply equipment.
- Orient Bio Inc. operates in a niche market with specific pathogen free animal services.
Opportunities
- Growing demand for biotechnology research in South Korea presents expansion potential.
- Increasing need for CRO services in new drug development across Asia.
- Orient Bio Inc. can leverage its laboratory animal services for global research partnerships.
Threats
- Competition from other biotechnology firms in South Korea's Health Care sector.
- Regulatory changes affecting laboratory animal supply chains in Asia.
- Economic downturns impacting funding for biotechnology research projects.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.